secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jade Biosciences, Inc. (JBIO)
CIK:        0001798749
Form:       8-K
Filed at:   2022-08-15T23:59:59+00:00
Accession:  0001493152-22-022588
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aerovate Therapeutics reports Q2 net loss of $12.0M; cash runway into H2 2025
-----------------------------------------------------------------------------

- Net loss $12.0M in Q2 2022 vs $5.8M in Q2 2021; R&D expenses $8.4M, G&A $3.9M.
- Cash and investments $152.0M as of June 30, 2022; expected to fund operations into H2 2025.
- IMPAHCT Phase 2b/Phase 3 trial ongoing; topline Phase 2b data expected Q4 2023 or Q1 2024.
- Phase 1 data for AV-101 showed well-tolerated and reduced systemic exposure vs oral imatinib.
- Strengthened management: Stephen Yu joined as SVP Quality with 20+ years pharma experience.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1798749/000149315222022588/0001493152-22-022588-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1798749/000149315222022588/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-022588

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer